IMIO Life

IMIO is a biotech company developing novel drug delivery systems for psychedelic therapies in order to enable the better penetration of molecules into the brain, reduce the therapeutic dose, and provide a safer treatment while minimizing adverse effects.

IMIO Life

IMIO is developing BTLS, a targeted liposomal delivery platform that has the ability to actively transport drugs through the blood-brain barrier directly into the brain. In preclinical studies, BLTS has enabled the targetted and specific delivery of specific drugs with minimal off-target effects. The company has chosen chronic pain as its lead indication.

IMIO is working with a number of companies in the space including MindMed.

“IMIO is dedicated to finding novel solutions for debilitating neurological disorders affecting millions of patients and their families. Our mission is to identify and refine the use of psychedelic molecules to better treat various neurological disorders.”